US 11,939,578 B2
Double-stranded RNA molecule targeting CKIP-1 and use thereof
Yanping Zhao, Beijing (CN); Hongjun Wang, Beijing (CN); Yuanyuan Jiang, Beijing (CN); Weiting Zhong, Beijing (CN); Jianmei Pang, Beijing (CN); Gong Li, Beijing (CN); Xiang Li, Beijing (CN); Yixin He, Beijing (CN); Liying Zhou, Beijing (CN); and Yanan Liu, Beijing (CN)
Assigned to BEIJING TIDE PHARMACEUTICAL CO., LTD., Beijing (CN)
Filed by BEIJING TIDE PHARMACEUTICAL CO., LTD., Beijing (CN)
Filed on Sep. 14, 2021, as Appl. No. 17/474,396.
Application 17/474,396 is a division of application No. 16/644,977, granted, now 11,155,819, previously published as PCT/CN2018/104552, filed on Sep. 7, 2018.
Claims priority of application No. PCT/CN2017/100863 (WO), filed on Sep. 7, 2017; application No. PCT/CN2017/100864 (WO), filed on Sep. 7, 2017; application No. PCT/CN2017/100865 (WO), filed on Sep. 7, 2017; application No. PCT/CN2017/100866 (WO), filed on Sep. 7, 2017; and application No. PCT/CN2017/100867 (WO), filed on Sep. 7, 2017.
Prior Publication US 2022/0064645 A1, Mar. 3, 2022
Int. Cl. C07H 21/04 (2006.01); A61P 19/02 (2006.01); A61P 19/08 (2006.01); A61P 29/00 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01); A61K 48/00 (2006.01)
CPC C12N 15/113 (2013.01) [A61P 19/02 (2018.01); A61P 19/08 (2018.01); A61P 29/00 (2018.01); C12N 15/85 (2013.01); A61K 48/00 (2013.01); C12N 2310/14 (2013.01); C12N 2310/314 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/334 (2013.01); C12N 2310/335 (2013.01)] 14 Claims
 
1. A pharmaceutical composition suitable for inhibiting casein kinase interacting protein 1 (CKIP-1) expression in a human subject in need thereof, which comprises:
(i) an amount of a double-stranded RNA (dsRNA) molecule comprising a sense strand shown in SEQ ID NO: 71 and an antisense strand shown in SEQ ID NO: 72 effective to inhibit the expression of CKIP-1 in a human subject in need thereof; and
(ii) a pharmaceutically acceptable carrier;
wherein said composition when administered to a human subject in need thereof is capable of inhibiting CKIP-1 expression.